RESUMEN
This study investigated the efficacy of co-administration of Spirulina platensis (SP) with vaccines on the immune response to Avian influenza (AI), Infectious bronchitis (IB), and Newcastle disease (ND), along with I/M challenging by virulent ND virus (vNDV) genotype VII. 126 one-day-old broiler chicks were allocated into six groups (21 birds/group with three replicates): G1: negative control; G2: positive control; G3: vaccinated, non-SP-supplemented; G4: vaccinated, SP-supplemented (0.1%); G5: vaccinated, SP-supplemented (0.3%); and G6: vaccinated, SP-supplemented (0.5%). G2-6 were challenged with a velogenic NDV genotype VII virus. Dietary SP administration prevented the ND-induced mortality compared to G2 (52.4%) and G3 (14.3%), in addition to alleviating the clinical disease. G3-6 showed significant improvement in body weight loss% and FCR during two weeks post vNDV challenge (pc), and the overall FCR (2.64 ± 0.28, 1.56 ± 0.03, 1.60 ± 0.05, 1.53 ± 0.04, and 1.54 ± 0.03 for G2, 3, 4, 5 and 6, respectively) (P<0.05). On the challenging day, the ND-HI titer (log2) of G3 (5.44 ± 0.24) was numerically higher than G6 (4.20 ± 0.55) and lower than G4 (6.10 ± 0.34) and G5 (6.00 ± 0.28). On the 10th day pc, ND-HI titer in G4-6 was numerically lower in a dose-dependent manner than that of G3, suggesting an antiviral efficacy of SP. G4-6 had lower viral shedding titer than G2 and G3 (P<0.05). In G3-6, viral shedding was reduced by 15, 27, 24, and 33.6%, respectively. In addition, the histopathological lesions in the trachea, lung, and spleen were severe in G2, moderately reduced in G3, and more relieved in G4-6. At three weeks after vaccination, the HI antibody titer of AIH5 was significantly higher after SP administration, especially at the 0.3% level, compared to the vaccine alone (P<0.05), demonstrating an immune-stimulating effect. In conclusion, dietary administration of SP, particularly a dose of 0.3%, for vaccinated chickens against NDV exerted an antiinflammatory and antiviral effects by preventing deaths, alleviating clinical disease and weight loss, and decreasing viral shedding post heterologous NDV challenge.